Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results

MT Newswires Live06-12

Shanghai Junshi Biosciences (HKG:1877) announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma (HCC), a type of liver cancer, according to a Tuesday filing on the Hong Kong bourse.

Toripalimab, along with bevacizumab, is being evaluated as a potential first-line treatment for this aggressive form of cancer.

Junshi Biosciences plans to submit a supplemental new drug application to regulatory authorities based on these trial results.

Junshi's shares were up over 1% in recent trading.

Price (HKD): $12.36, Change: $+0.18, Percent Change: +1.48%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2442029302?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-12 14:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2442029302","market":"nz","top_or_hot":-1,"title":"Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results","media":"MT Newswires Live","content":"<html><body><p> Shanghai Junshi Biosciences (HKG:1877) announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma (HCC), a type of liver cancer, according to a Tuesday filing on the Hong Kong bourse.  </p><p>Toripalimab, along with bevacizumab, is being evaluated as a potential first-line treatment for this aggressive form of cancer.</p><p>Junshi Biosciences plans to submit a supplemental new drug application to regulatory authorities based on these trial results.</p><p>Junshi's shares were up over 1% in recent trading. </p><p>Price (HKD): $12.36, Change: $+0.18, Percent Change: +1.48%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Junshi Biosciences Cancer Drug Shows Positive Phase III Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-12 14:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Junshi Biosciences (HKG:1877) announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma (...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2442029302","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2442029302","pubTimestamp":1718172888,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Junshi Biosciences  announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma , a type of liver cancer, according to a Tuesday filing on the Hong Kong bourse.  Toripalimab, along with bevacizumab, is being evaluated as a potential first-line treatment for this aggressive form of cancer.Junshi Biosciences plans to submit a supplemental new drug application to regulatory authorities based on these trial results.Junshi's shares were up over 1% in recent trading. Price : $12.36, Change: $+0.18, Percent Change: +1.48%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"III":"信息服务","HCC":"Warrior Met Coal LLC","BK4134":"信息科技咨询与其它服务","BK4588":"碎股","BK4023":"应用软件","BK1583":"高瓴概念","HKD":"尚乘数科","BK4585":"ETF&股票定投概念","BK1515":"抗疫概念","BK1161":"生物科技","BK4006":"钢铁","BK4526":"热门中概股","01877":"君实生物"},"translate_title":"上海君实生物抗癌药三期试验结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCC":1,"HKD":1,"III":1,"01877":0.9},"content_text":"Shanghai Junshi Biosciences (HKG:1877) announced positive results from a Phase III clinical trial testing its drug toripalimab in combination with bevacizumab for advanced hepatocellular carcinoma (HCC), a type of liver cancer, according to a Tuesday filing on the Hong Kong bourse.  Toripalimab, along with bevacizumab, is being evaluated as a potential first-line treatment for this aggressive form of cancer.Junshi Biosciences plans to submit a supplemental new drug application to regulatory authorities based on these trial results.Junshi's shares were up over 1% in recent trading. Price (HKD): $12.36, Change: $+0.18, Percent Change: +1.48%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2442029302"}